Skip to main content
. 2023 Aug 30;11(8):e007202. doi: 10.1136/jitc-2023-007202

Figure 1.

Figure 1

Impact of NKG2A and NKG2D gene variants on outcome of immunotherapy in AML. (A) Leukemia-free survival of AML patients carrying NKG2A (rs1983526) GG (n=27), CG (n=44) or CC (n=9), after receiving HDC/IL-2 treatment. (B) Leukemia-free survival of AML patients based on NKG2D (rs1049174) GG (n=11), CG (n=37) or CC (n=32), after receiving HDC/IL-2 treatment. AML, acute myeloid leukemia; HDC, histamine dihydrochloride; LFS, leukemia-free survival.